Publicaciones (72) Publicaciones en las que ha participado algún/a investigador/a

2020

  1. 4-1BB (CD137) in anticancer chimeras

    Journal of Experimental Medicine, Vol. 217, Núm. 12

  2. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

    Blood Advances, Vol. 4, Núm. 23, pp. 5988-5999

  3. A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia

    Blood Cancer Journal, Vol. 10, Núm. 1

  4. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

    Leukemia, Vol. 34, Núm. 1, pp. 224-233

  5. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study

    EClinicalMedicine, Vol. 25

  6. Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection. A Spanish consensus document

    Bone Marrow Transplantation, Vol. 55, Núm. 4, pp. 811-817

  7. Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?

    Molecular Therapy - Nucleic Acids, Vol. 21, pp. 192-204

  8. Article18 f-fdg and11 c-methionine pet/ct in newly diagnosed multiple myeloma patients: Comparison of volume-based pet biomarkers

    Cancers, Vol. 12, Núm. 4

  9. Assessment of minimal residual disease by next generation sequencing in peripheral blood as a complementary tool for personalized transplant monitoring in myeloid neoplasms

    Journal of Clinical Medicine, Vol. 9, Núm. 12, pp. 1-20

  10. Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design

    PLoS ONE, Vol. 15, Núm. 1

  11. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

    The Lancet Oncology, Vol. 21, Núm. 2, pp. 207-221

  12. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

    Blood, Vol. 135, Núm. 26, pp. 2375-2387

  13. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

  14. Car t-cells in multiple myeloma are ready for prime time

    Journal of Clinical Medicine, Vol. 9, Núm. 11, pp. 1-16

  15. Cells, Materials, and Fabrication Processes for Cardiac Tissue Engineering

    Frontiers in Bioengineering and Biotechnology, Vol. 8

  16. Cellular cytotoxicity is a form of immunogenic cell death

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

  17. Characterization of freshly isolated mesenchymal stromal cells from healthy and multiple myeloma bone marrow: Transcriptional modulation of the microenvironment.

    Haematologica, Vol. 105, Núm. 5

  18. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

    Genome Research, Vol. 30, Núm. 9, pp. 1217-1227

  19. Circulating TIMP-1 is associated with hematoma volume in patients with spontaneous intracranial hemorrhage

    Scientific Reports, Vol. 10, Núm. 1

  20. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

    Leukemia, Vol. 34, Núm. 11, pp. 3007-3018